System Administrator, Identity & Access Management

4+ years of hands-on systems administration experience, with at least 2 years with explicit IAM responsibility.

Strong understanding of IAM principles: identity lifecycle, RBAC, least privilege, separation of duties, access certification, and privileged access management.

Experience administering B2B / guest identities and external collaboration controls

Working knowledge of non-human identity management: service principals, managed identities, workload identity federation, and secret/certificate rotation.

Experience designing and operating SSO and SCIM provisioning integrations for SaaS applications

Experience with low-code automation platforms for workflow and integration automation.

Dianthus is growing quickly, and we are looking for a hands-on Systems Administrator with strong Identity and Access Management (IAM) expertise to help us scale securely.  You will be the operational owner of our identity platform and access governance program, responsible for “who — and what — has access to what”, covering employee, contractor, external partner (B2B), and non-human (service) identities.

This is a high impact role where you will shape our identity lifecycle, strengthen our security posture, and support our SaaS and endpoint environment as we prepare for commercial scale.

We are building a culture of individuals who hold our core principles at the center of our operations, with the goal to elevate the care of our patients’ lives.

We are developing potentially best in class therapies for patients living with severe autoimmune diseases. Our lead antibody, claseprubart (DNTH103), is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections. Our second clinical candidate, DNTH212 is a first and potentially best in class, bifunctional inhibitor that targets clinically validated and complementary disease modifying mechanisms, Type 1 IFN suppression and B cell modulation – enabling potential for improved clinical outcomes and patient friendly convenient, self-administered subcutaneous injections. To learn more, please visit

www.dianthustx.com

and follow us on

LinkedIn

.